Cover Image

Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study

Abstract This study aimed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of vutiglabridin, a potential anti‐obesity treatment under development, for the first time in humans. A randomized, placebo‐controlled, single‐ and multiple‐ascending dose study (SAD and MAD, respe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Joo Young Na (Author), Deok Yong Yoon (Author), Hyounggyoon Yoo (Author), SeungHwan Lee (Author), Kyung‐Sang Yu (Author), In‐Jin Jang (Author), Sang‐Ku Yoo (Author), Youngah Kim (Author), Jaeseong Oh (Author)
Format:	Book
Published:	Wiley, 2022-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effects of meal type on the bioavailability of vutiglabridin, a novel anti‐obesity agent, in healthy subjects
by: Heejae Won, et al.
Published: (2024)

Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects
by: JungJin Oh, et al.
Published: (2023)

Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects
by: Min Young Park, et al.
Published: (2023)

Semimechanistic pharmacokinetic-pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy
by: Soyoung Lee, et al.
Published: (2023)

Single‐dose of LC51‐0255, a selective S1P1 receptor modulator, showed dose‐dependent and reversible reduction of absolute lymphocyte count in humans
by: Sang Won Lee, et al.
Published: (2022)

Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects
by: Inyoung Hwang, et al.
Published: (2022)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
by: Deok Y. Yoon, et al.
Published: (2021)

Safety, Tolerability, and Serum/Tear Pharmacokinetics of Human Recombinant Epidermal Growth Factor Eyedrops in Healthy Subjects
by: Hyounggyoon Yoo, et al.
Published: (2022)

Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers
by: Woo Kyung Chung, et al.
Published: (2023)

Vutiglabridin Alleviates Cellular Senescence with Metabolic Regulation and Circadian Clock in Human Dermal Fibroblasts
by: Jin-Woong Heo, et al.
Published: (2024)

Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease
by: Xuanyou Jin, et al.
Published: (2020)

Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration
by: Sungyeun Bae, et al.
Published: (2023)

Prediction of gastric pH‐mediated drug exposure using physiologically‐based pharmacokinetic modeling: A case study of itraconazole
by: Eunsol Yang, et al.
Published: (2023)

Impact of Vancomycin‐Induced Changes in the Intestinal Microbiota on the Pharmacokinetics of Simvastatin
by: Jung Sunwoo, et al.
Published: (2020)

Feasibility study for a fully decentralized clinical trial in participants with functional constipation symptoms
by: Ki Young Huh, et al.
Published: (2023)

Reversal of rocuronium‐induced intense neuromuscular blockade by sugammadex in Korean children: A pharmacokinetic and pharmacodynamic analysis
by: Sang‐Hwan Ji, et al.
Published: (2023)

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers
by: Shin W, et al.
Published: (2019)

Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
by: Yoon S, et al.
Published: (2015)

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
by: Tingting Ma, et al.
Published: (2022)

A first‐in‐human study of KMRC011, a potential treatment for acute radiation syndrome, to explore tolerability, pharmacokinetics, and pharmacodynamics
by: Eunsol Yang, et al.
Published: (2021)

The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses
by: Yuanxun Yang, et al.
Published: (2024)

The pharmacokinetic, safety, and tolerability profiles of eslicarbazepine acetate are comparable between Korean and White subjects
by: Sejung Hwang, et al.
Published: (2022)

Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase
by: Jihyun Kang, et al.
Published: (2022)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
by: Xu HR, et al.
Published: (2016)

First‐in‐human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS‐penetrant soluble guanylyl cyclase stimulator
by: Sebastiaan J. W. vanKraaij, et al.
Published: (2023)

First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects
by: Jing Yang, et al.
Published: (2021)

Caffeine Produced in Rice Plants Provides Tolerance to Water-Deficit Stress
by: Youngchul Yoo, et al.
Published: (2023)

Pioglitazone‐induced alterations of purine metabolism in healthy male subjects
by: Jihyun Kang, et al.
Published: (2024)

A randomized, placebo‐controlled first‐in‐human study of oral TQS‐168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect
by: Jonas Hannestad, et al.
Published: (2024)

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
by: Hwang I, et al.
Published: (2020)

A phase I study to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profiles of ocular GLH8NDE in healthy male adults
by: Jihyun Jung, et al.
Published: (2022)

Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first‐in‐human and first‐in‐patient trials
by: Matthew P. Kosloski, et al.
Published: (2022)

Pharmacokinetics and safety of cenobamate, a novel antiseizure medication, in healthy Japanese, and an ethnic comparison with healthy non‐Japanese
by: Eunsol Yang, et al.
Published: (2022)

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
by: Jeon I, et al.
Published: (2021)

A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects
by: Xu Jiang, et al.
Published: (2024)

Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019
by: Ki Young Huh, et al.
Published: (2021)

The necessary conduct: Exploratory multiregional clinical trials in East Asia
by: Inseung Jeon, et al.
Published: (2021)

Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Lien Thi Ngo, et al.
Published: (2020)

A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects
by: Park SI, et al.
Published: (2015)

Exploration of smart adherence‐monitoring methods in vitamin D‐deficient patients: A pilot feasibility clinical study
by: Ki Young Huh, et al.
Published: (2023)